PerformanceRiskValuationProfitabilityCashflowLiquidityESGRevenue & Geographic ExposureForecastFinancial GrowthIncome GrowthCashflow GrowthBalance Sheet Growth
Actinium Pharmaceuticals, Inc. (ATNM)
1.780.01 (-0.56%)
1.75 - 1.81
1.03 - 2.41
122.5K / 297.6K (Avg.)
-1.36 | -1.31
Helps investors judge whether earnings growth is driven by sustainable operations or temporary factors. Consistent, organic income expansion can justify a higher intrinsic value for patient, long-term investors.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
37.07%
R&D growth above 1.5x GNPX's 12.70%. Michael Burry would check for spending discipline.
-49.28%
Both companies reducing G&A. Martin Whitman would check industry cost trends.
No Data
No Data available this quarter, please select a different quarter.
3.11%
Other expenses change of 3.11% while GNPX maintains costs. Bruce Berkowitz would investigate efficiency.
2.64%
Operating expenses growth while GNPX reduces costs. John Neff would investigate differences.
2.64%
Total costs growth while GNPX reduces costs. John Neff would investigate differences.
-60.43%
Interest expense reduction while GNPX shows 0.00% growth. Joel Greenblatt would examine advantage.
3.11%
D&A change of 3.11% while GNPX maintains D&A. Bruce Berkowitz would investigate efficiency.
0.38%
EBITDA growth below 50% of GNPX's 65.56%. Michael Burry would check for structural issues.
No Data
No Data available this quarter, please select a different quarter.
-2.64%
Operating income decline while GNPX shows 65.55% growth. Joel Greenblatt would examine position.
No Data
No Data available this quarter, please select a different quarter.
70.91%
Other expenses change of 70.91% while GNPX maintains costs. Bruce Berkowitz would investigate control.
0.38%
Pre-tax income growth below 50% of GNPX's 65.55%. Michael Burry would check for structural issues.
No Data
No Data available this quarter, please select a different quarter.
-60.43%
Tax expense reduction while GNPX shows 0.00% growth. Joel Greenblatt would examine advantage.
0.38%
Net income growth below 50% of GNPX's 65.55%. Michael Burry would check for structural issues.
No Data
No Data available this quarter, please select a different quarter.
3.04%
EPS growth below 50% of GNPX's 64.91%. Michael Burry would check for structural issues.
3.04%
Diluted EPS growth below 50% of GNPX's 65.11%. Michael Burry would check for structural issues.
2.54%
Share count increase while GNPX reduces shares. John Neff would investigate differences.
2.54%
Diluted share increase while GNPX reduces shares. John Neff would investigate differences.